Article
Reduction in Human Papillomavirus Vaccine Type Prevalence Among Young Women Screened for Cervical Cancer in an Integrated US Healthcare Delivery System in 2007 and 2012-2013.
The Journal of infectious diseases - 15 Dec 2015
Dunne Eileen F, Naleway Allison, Smith Ning, Crane Bradley, Weinmann Sheila, Braxton Jim, Steinau Martin, Unger Elizabeth R, Markowitz Lauri E
Abstract excerpt
BACKGROUND: In the United States, human papillomavirus (HPV) vaccine is recommended for 11- or 12-year-olds, and for young adults not previously vaccinated. Early vaccine impact can be measured by reductions in vaccine-type (VT) HPV prevalence. METHODS: Consecutive residual cervical specimens were retained from women aged 20-29 years at Kaiser Permanente Northwest in 2007, 2012, and 2013. HPV genotypes were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.